Is Relay Therapeutics, Inc. (RLAY) Overvalued?
We dive into why Relay Therapeutics, Inc. (RLAY) could be considered overvalued on 2026-07-30, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Relay Therapeutics, Inc.’s (RLAY) Stock Is Down 6.57%
As of Monday, July 13, Relay Therapeutics, Inc.’s RLAY share price has dipped by 6.57%, which has investors questioning if this is right time to buy.Jenna Brashear
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or Relay Therapeutics, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or Relay Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why Relay Therapeutics, Inc.’s (RLAY) Stock Is Down 5.25%
As of Friday, July 10, Relay Therapeutics, Inc.’s RLAY share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Michael Rose
Why Relay Therapeutics, Inc.’s (RLAY) Stock Is Down 5.67%
As of Wednesday, July 08, Relay Therapeutics, Inc.’s RLAY share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | RLAY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,103.8 | $252.6 | 64% |
|
| Shares Out (Mil) | 179.8 | 52.3 | 74% |
|
| Institutional Ownership | 97.0% | 92.1% | 72% |
|
| Float (Mil) | 154.9 | 40.2 | 70% |
|
| Beta | 1.75 | 0.95 | 88% |
|
| Avg Daily Volume (000s) | 2,231 | 455 | 84% |
|
| Price Change (52-week) |
418.7% | 52.9% | 99% |
|
| Growth | RLAY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (28.5%) | 13.6% | 1% |
|
| Net Income (5yr) | (39.5%) | (9.9%) | 9% |
|
| EPS (5yr) | 21.5% | 16.0% | 70 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.2%) | (15.6%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 10 | 8 | |
| Current EPS | ($0.393) | ($1.526) | ($1.641) | |
| Month Ago EPS | ($0.397) | ($1.519) | ($1.651) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.390) | ($1.522) | ($1.572) | |
| Year/Year Chg | (3.7%) | (5.3%) | (6.0%) | |
| Financials | RLAY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11 | $38 | 9% |
|
| Net Income (TTM) (Mil) | ($273) | ($43) | 5% |
|
| EPS (TTM) | ($1.565) | ($1.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($213) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $110 | $5 | 78% |
|
| Long-Term Debt (Q1) (Mil) | $28 | $5 | 35% |
|
| Enterprise Value (Q1) (Mil) | $1,727 | $180 | 48% |
|
| Valuation | RLAY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.55 | 2.56 | 81% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RLAY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (36.4%) | (49.8%) | 15% |
|
| ROE | (40.0%) | (55.5%) | 17% |
|
| Liabilities to Assets | 8.2% | 30.3% | 4% |
|
| F-Score | 4 | 3 | 34% |
|
Relay Therapeutics, Inc. did not pass any screens on 7/31/2026.
